Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development
Vancouver, British Columbia and New York, New York--(Newsfile Corp. - August 13, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX:...
Pharmaceutical
Therma Bright Welcomes Medical & Pharmaceutical Veteran Michael Raimondo to Its Advisory Board
New Advisory Board Member Will Initially Focus On Venowave Sales & Business DevelopmentToronto, Ontario--(Newsfile Corp. - August 13, 2024) -...
Defence Therapeutics Collaboration Agreement with Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer Advances
Vancouver, British Columbia--(Newsfile Corp. - August 13, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or...
New Scientific Article on NeuroRestore ACD856 and its Improved Cognition and Disease Modification of Alzheimer’s Disease
STOCKHOLM, SE / ACCESSWIRE / August 13, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical...
Evotec Announces Strong Progress in Strategic Protein Degradation Partnership with Bristol Myers Squibb
Key scientific achievements drive the expansion of the pipeline of molecular glue degradersPerformance-based and programme-based payments of in total US$...
/R E P E A T — Claigan Webinar – Canadian PFAS Reporting New – Section 71 Reporting of PFAS in Canada/
OTTAWA, ON, Aug. 8, 2024 /PRNewswire/ - On August 14, Claigan Environmental Inc. (www.claigan.com) will be presenting a webinar on...
REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients
Jaguar to explore approval pathway for crofelemer in breast and lung cancer based on phase 3 resultsClick here to register...
Orphan Drugs and Rare Diseases Conference (Boston, MA, United States – October 17-18, 2024) – Navigating Orphan Drugs & Rare Diseases from Regulation to Detection & Precision Treatments – ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Orphan Drugs and Rare Diseases Conference" has been added to ResearchAndMarkets.com's offering. The 2 day Orphan Drugs and...
MIRA Pharmaceuticals Unveils Ketamir-2’s Principal Metabolite: Nor-Ketamir – a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
This breakthrough in bioavailability and formulation showcases the potential for advanced, at home neurological treatments.MIAMI, FL / ACCESSWIRE / August...
Theralase(R) Release’s 2Q2024 Financial Statements
TORONTO, ON / ACCESSWIRE / August 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
Parexel’s Near-Term Greenhouse Gas Reduction Targets Validated by Science Based Target Initiative (SBTi)
DURHAM, N.C., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the...
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1...
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to...
FSD Pharma Announces Share Consolidation and Name Change
Toronto, Ontario--(Newsfile Corp. - August 9, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9) ("FSD Pharma" or...
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2025 Financial Results on August 15, 2024
Financials for First Quarter of Fiscal Year 2025 Ended June 30, 2024 will be released on August 14, 2024Northvale, New...
Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024
WOBURN, MA / ACCESSWIRE / August 9, 2024 / Biofrontera Inc. (Nasdaq:BFRI), a biopharmaceutical company specializing in the commercialization of...
FSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month – Created by a World-Class Pharmaceutical Research & Development Team
TORONTO, ON / ACCESSWIRE / August 9, 2024 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), provides an update on its...
Celly Nutrition Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month – Created by a World-Class Pharmaceutical Research & Development Team
Vancouver, British Columbia--(Newsfile Corp. - August 9, 2024) - Celly Nutrition Corp. ("Celly Nu" or the "Company"), which is backed...
Ginkgo Bioworks Reports Second Quarter 2024 Financial Results
Ginkgo provides update on its restructuring process including estimated annualized cost savings of over $85 million from reduction in force ...
Catalyst Clinical Research Announces First CCO
Kristin Judge assumes leadership role for all commercial functions WILMINGTON, N.C., Aug. 8, 2024 /PRNewswire/ -- Catalyst Clinical Research announced today...